Drug intelligence / Profile preview

furaprevir + peg-interferon alfa-2a + ribavirin

Development stage: Unknown
Lead developer: Roche
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral (furaprevir, Ribavirin), Subcutaneous (peg-interferon Alfa-2a)

Overview

A **combination therapy** of **furaprevir** (an investigational NS3 protease inhibitor), **peg-interferon alfa-2a** (a pegylated interferon used as an immunomodulator and antiviral), and **ribavirin** (a nucleoside analogue antiviral), investigated for treatment of **chronic hepatitis C virus (HCV) infection**. - **Furaprevir** inhibits the NS3 serine protease required for HCV polyprotein processing and replication. - **Peg-interferon alfa-2a** enhances host immune response and exerts antiviral effects via interferon-stimulated genes. - **Ribavirin** likely induces lethal mutagenesis in virions and inhibits viral RNA synthesis. This combination would aim for synergistic inhibition of HCV replication across multiple stages and mechanisms, mainly in patients with chronic HCV; furaprevir is not yet widely studied or approved, whereas peg-interferon alfa-2a + ribavirin has established efficacy and approval as a dual therapy.

Brand names: Pegasys (for peg-interferon alfa-2a)none known for this specific combination
Other names: none known for this exact triple combination

Targets

IFNAR (Immune system modulation via type I interferon receptor)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on furaprevir + peg-interferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on furaprevir + peg-interferon alfa-2a + ribavirin.

Explore the full profile